Literature DB >> 324694

Relationship between blood level of atenolol and pharmacologic effect.

A Amery, J F De Plaen, P Lijnen, J McAinsh, T Reybrouck.   

Abstract

Thirty-five hypertensive patients were treated with atenolol in weekly increasing doses (25, 50, 100, and 200 mg thrice daily). Factors determining the blood level of the drug were studied along with the relationship between blood level, the degree of cardiac beta blockade, and the antihypertensive effect of the drug. The blood level obtained varied with the daily dose, the time of blood sampling during the day, the body weight, and the creatinine clearance. The degree of beta blockade was assessed by measuring maximum-exercise tachycardia and was correlated with the blood level of atenolol. The reduction of the maximum exercise heart rate was independent of age. The hypotensive effect was not closely correlated with the blood level. Three days after the termination of long-term atenolol treatment, blood levels and beta blockage were still detectable.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324694     DOI: 10.1002/cpt1977216691

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  The implications of noncompliance with antihypertensive medication.

Authors:  B Girvin; G D Johnston
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

3.  Comparison of disposition and effect of timolol and propranolol on exercise tachycardia.

Authors:  T Ishizaki; K Tawara
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

4.  Comparison of atenolol 50 mg and 100 mg as initial treatment in uncomplicated mild to moderate hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration.

Authors:  G Leonetti; L Terzoli; C Bianchini; C Sala; A Zanchetti
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

6.  Antihypertensive effect of atenolol alone or combined with chlorthalidone in patients with essential hypertension.

Authors:  M Velasco; J Guevara; J Morillo; A Ramírez; A Urbina-Quintana; O Hernández-Pieretti
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

7.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Abrupt withdrawal of atenolol in patients with severe angina. Comparison with the effects of treatment.

Authors:  P R Walker; A J Marshall; S Farr; B Bauminger; G Walters; D W Barritt
Journal:  Br Heart J       Date:  1985-03

9.  Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.

Authors:  J D Fitzgerald; R Ruffin; K G Smedstad; R Roberts; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

10.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lisa M Wruck; Timothy J Bradley; Steven D Colan; Richard B Devereux; Gloria L Klein; Jennifer S Li; L LuAnn Minich; Stephen M Paridon; Gail D Pearson; Beth F Printz; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; J Philip Saul; Mario P Stylianou; Lynn Mahony
Journal:  Am Heart J       Date:  2007-10       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.